FONT-SIZE Plus   Neg

CER Research Says Abbott's Response To Similac Test Results Irresponsible

Hong Kong-based CER Research Friday said Abbott Laboratories Inc.'s (ABT) response to the report released March 22 relating to the safety of the infant formula product Similac Stage 1 was "irresponsible." The report contained results which showed that the Abbott product, purchased in Hong Kong in December, failed two tests by a significant margin.

In its response, which, according to CER Research, was issued in Chinese, Abbott criticized the report for a lack of "scientific-ness, objectivity and fairness." CER Research's rebuttal claims that the results were obtained from "named and recognized laboratories and experts", adding that it has "no independent view" on the product. Further, CER Research said its attempts to contact Abbott were rebuffed.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Earnings at banking giant JP Morgan Chase (JPM) jumped more than 20% compared to last year, despite a decline in revenue. The firm's bottom line received a boost from about $2 billion in tax benefits. Computer chip maker Intel (INTC) announced earnings for the third quarter that slipped about 6 percent from last year. Still, the bottom line came in above the amount predicted by market analysts, as Wall Street had predicted a more pronounced decline. Intel benefited from gains in its Data Center and Internet units, but saw year-over-year weakness in its Client Computing division. Starbucks is rolling out its delivery service - good news for any caffeine addicts who can't make it out to the coffee chain. Unfortunately, there's still a wait in store for most people: the new service only covers Manhattan's most recognizable skyscraper. According to multiple media reports, Starbucks' pilot program is launching at the Empire State Building in New York City.
comments powered by Disqus
Trade ABT now with 
Follow RTT